Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT (Reuters) - German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news